Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982760 · ClinicalTrials.gov registry record · Phase 2
DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty
A Phase 2 study, sponsored by University Hospitals Cleveland Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01982760: Clinical Trial Phase 2 study, sponsored by University Hospitals Cleveland Medical Center.
NCT01982760 is a Phase 2 study that was terminated before completion, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01982760, a Phase 2 study, was terminated before completion, sponsored by University Hospitals Cleveland Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a drug used in patients with bleeding disorders. It works by activating molecules in the blood stream called platelets that promote clotting. In the study, participants who are have cosmetic nose surgery (rhinoplasty) will be randomly assigned to receive or not receive medication. Photographs taken before and shortly after surgery will be evaluated for the amount of bruising and swelling. Patients with heart, lung, kidney, or liver problems are not eligible to participate.
Primary Outcome
Photographs taken preoperatively at 1 day and 8 days post-operatively will be analyzed for bruising
Interventions
- DRUG DDAVP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-06-25 |
| Phase | Phase 2 |
Why NCT01982760 stopped before completion
NCT01982760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which DDAVP is the first listed.
NCT01982760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01982760 about?
NCT01982760 is a clinical study titled "DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty". This is study looking at the use of a medication, Desmopressin acetate (DDAVP), to reduce bleeding, swelling, and bruising in patients undergoing cosmetic nose surgery. DDAVP is a drug used in patients with bleeding disorders. It works by activating molecules in the blood stream called platelets tha...
What is the current status of trial NCT01982760?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2013-12. Estimated completion is 2015-06-25.
What interventions are being tested in trial NCT01982760?
The interventions under investigation include: DDAVP (DRUG).
Who is sponsoring clinical trial NCT01982760?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01982760's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia